401 related articles for article (PubMed ID: 27897418)
1. Suppression of muscle wasting by the plant-derived compound ursolic acid in a model of chronic kidney disease.
Yu R; Chen JA; Xu J; Cao J; Wang Y; Thomas SS; Hu Z
J Cachexia Sarcopenia Muscle; 2017 Apr; 8(2):327-341. PubMed ID: 27897418
[TBL] [Abstract][Full Text] [Related]
2. Transcription factor FoxO1, the dominant mediator of muscle wasting in chronic kidney disease, is inhibited by microRNA-486.
Xu J; Li R; Workeneh B; Dong Y; Wang X; Hu Z
Kidney Int; 2012 Aug; 82(4):401-11. PubMed ID: 22475820
[TBL] [Abstract][Full Text] [Related]
3. Suppression of atrogin-1 and MuRF1 prevents dexamethasone-induced atrophy of cultured myotubes.
Castillero E; Alamdari N; Lecker SH; Hasselgren PO
Metabolism; 2013 Oct; 62(10):1495-502. PubMed ID: 23866982
[TBL] [Abstract][Full Text] [Related]
4. Long-noncoding RNA Atrolnc-1 promotes muscle wasting in mice with chronic kidney disease.
Sun L; Si M; Liu X; Choi JM; Wang Y; Thomas SS; Peng H; Hu Z
J Cachexia Sarcopenia Muscle; 2018 Oct; 9(5):962-974. PubMed ID: 30043444
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of muscle wasting in chronic kidney disease.
Wang XH; Mitch WE
Nat Rev Nephrol; 2014 Sep; 10(9):504-16. PubMed ID: 24981816
[TBL] [Abstract][Full Text] [Related]
6. The nuclear phosphatase SCP4 regulates FoxO transcription factors during muscle wasting in chronic kidney disease.
Liu X; Yu R; Sun L; Garibotto G; Lin X; Wang Y; Thomas SS; Li R; Hu Z
Kidney Int; 2017 Aug; 92(2):336-348. PubMed ID: 28506762
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms stimulating muscle wasting in chronic kidney disease: the roles of the ubiquitin-proteasome system and myostatin.
Thomas SS; Mitch WE
Clin Exp Nephrol; 2013 Apr; 17(2):174-82. PubMed ID: 23292175
[TBL] [Abstract][Full Text] [Related]
8. IMB0901 inhibits muscle atrophy induced by cancer cachexia through MSTN signaling pathway.
Liu D; Qiao X; Ge Z; Shang Y; Li Y; Wang W; Chen M; Si S; Chen SZ
Skelet Muscle; 2019 Mar; 9(1):8. PubMed ID: 30922397
[TBL] [Abstract][Full Text] [Related]
9. Matrine improves skeletal muscle atrophy by inhibiting E3 ubiquitin ligases and activating the Akt/mTOR/FoxO3α signaling pathway in C2C12 myotubes and mice.
Chen L; Chen L; Wan L; Huo Y; Huang J; Li J; Lu J; Xin B; Yang Q; Guo C
Oncol Rep; 2019 Aug; 42(2):479-494. PubMed ID: 31233199
[TBL] [Abstract][Full Text] [Related]
10. Signal regulatory protein-α interacts with the insulin receptor contributing to muscle wasting in chronic kidney disease.
Thomas SS; Dong Y; Zhang L; Mitch WE
Kidney Int; 2013 Aug; 84(2):308-16. PubMed ID: 23515050
[TBL] [Abstract][Full Text] [Related]
11. Chronic Alcohol Consumption Enhances Skeletal Muscle Wasting in Mice Bearing Cachectic Cancers: The Role of TNFα/Myostatin Axis.
Li Y; Zhang F; Modrak S; Little A; Zhang H
Alcohol Clin Exp Res; 2020 Jan; 44(1):66-77. PubMed ID: 31657476
[TBL] [Abstract][Full Text] [Related]
12. S-allyl cysteine inhibits TNFα-induced skeletal muscle wasting through suppressing proteolysis and expression of inflammatory molecules.
Dutt V; Saini V; Gupta P; Kaur N; Bala M; Gujar R; Grewal A; Gupta S; Dua A; Mittal A
Biochim Biophys Acta Gen Subj; 2018 Apr; 1862(4):895-906. PubMed ID: 29288771
[TBL] [Abstract][Full Text] [Related]
13. Sarcopenia in Chronic Kidney Disease: Factors, Mechanisms, and Therapeutic Interventions.
Watanabe H; Enoki Y; Maruyama T
Biol Pharm Bull; 2019; 42(9):1437-1445. PubMed ID: 31474705
[TBL] [Abstract][Full Text] [Related]
14. Myricanol rescues dexamethasone-induced muscle dysfunction via a sirtuin 1-dependent mechanism.
Shen S; Liao Q; Liu J; Pan R; Lee SM; Lin L
J Cachexia Sarcopenia Muscle; 2019 Apr; 10(2):429-444. PubMed ID: 30793539
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological inhibition of myostatin suppresses systemic inflammation and muscle atrophy in mice with chronic kidney disease.
Zhang L; Rajan V; Lin E; Hu Z; Han HQ; Zhou X; Song Y; Min H; Wang X; Du J; Mitch WE
FASEB J; 2011 May; 25(5):1653-63. PubMed ID: 21282204
[TBL] [Abstract][Full Text] [Related]
16. Targeting the myostatin signaling pathway to treat muscle wasting diseases.
Han HQ; Mitch WE
Curr Opin Support Palliat Care; 2011 Dec; 5(4):334-41. PubMed ID: 22025090
[TBL] [Abstract][Full Text] [Related]
17. Valproic acid attenuates skeletal muscle wasting by inhibiting C/EBPβ-regulated atrogin1 expression in cancer cachexia.
Sun R; Zhang S; Hu W; Lu X; Lou N; Yang Z; Chen S; Zhang X; Yang H
Am J Physiol Cell Physiol; 2016 Jul; 311(1):C101-15. PubMed ID: 27122162
[TBL] [Abstract][Full Text] [Related]
18. β-Hydroxy-β-methylbutyrate (HMB) prevents dexamethasone-induced myotube atrophy.
Aversa Z; Alamdari N; Castillero E; Muscaritoli M; Rossi Fanelli F; Hasselgren PO
Biochem Biophys Res Commun; 2012 Jul; 423(4):739-43. PubMed ID: 22705301
[TBL] [Abstract][Full Text] [Related]
19. Amelioration of muscle wasting by glucagon-like peptide-1 receptor agonist in muscle atrophy.
Hong Y; Lee JH; Jeong KW; Choi CS; Jun HS
J Cachexia Sarcopenia Muscle; 2019 Aug; 10(4):903-918. PubMed ID: 31020810
[TBL] [Abstract][Full Text] [Related]
20. The G protein-coupled receptor ligand apelin-13 ameliorates skeletal muscle atrophy induced by chronic kidney disease.
Enoki Y; Nagai T; Hamamura Y; Osa S; Nakamura H; Taguchi K; Watanabe H; Maruyama T; Matsumoto K
J Cachexia Sarcopenia Muscle; 2023 Feb; 14(1):553-564. PubMed ID: 36562292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
